James P. Brady

Human Resources Officer at SPERO THERAPEUTICS, INC.

Health Technology

Consumer Services

Profile

James P.
Brady is currently the Chief Human Resource Officer at Spero Therapeutics, Inc. Previously, he held the position of Vice President-Human Resources at Intarcia Therapeutics, Inc. and was the Chief Human Resources Officer at uniQure NV.
He received a graduate degree from Harvard University and an undergraduate degree from Marietta College.

James P. Brady active positions

Companies	Position	Start
SPERO THERAPEUTICS, INC.	Human Resources Officer	-

All active positions of James P. Brady

Former positions of James P. Brady

Companies	Position	End
UNIQURE N.V.	Human Resources Officer	-
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Human Resources Officer	-

See the detail of James P. Brady's experience

Training of James P. Brady

Harvard University	Graduate Degree
Marietta College	Undergraduate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of James P. Brady's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	2
UNIQURE N.V.	Health Technology
SPERO THERAPEUTICS, INC.	Health Technology

Private companies	1
Intarcia Therapeutics, Inc. Intarcia Therapeutics, Inc. BiotechnologyHealth Technology Intarcia Therapeutics, Inc. develops therapies for the treatment of chronic diseases. Its lead product candidate, ITCA 650, is currently in development for the treatment of type 2 diabetes. The firm’s platform technology is a proprietary subcutaneous delivery system that involves a matchstick-size, miniature osmotic pump implanted sub-dermally to provide continuous and consistent drug therapy, and the company’s proprietary formulation technology, which maintains stability of therapeutic proteins and peptides at human body temperatures for long extended periods of time. The company was founded by Mark Moran in June 1995 and is headquartered in Boston, MA.	Health Technology